Omeros Corp. has announced that it recently submitted a new drug application to the FDA for approval of a new drug for use in patients undergoing IOL replacement (ILR) surgery.
Seattle-Omeros Corp. has announced that it recently submitted a new drug application to the FDA for approval of a new drug for use in patients undergoing IOL replacement (ILR) surgery.
Added to the standard irrigation solution used during ILR, the new drug, OMS203, has demonstrated clinically meaningful and statistically significant maintenance of intraoperative mydriasis, prevention of intraoperative miosis and reduction of postoperative ocular pain.
“OMS302 fills a need recognized by all ophthalmic surgeons and does so without requiring them to change their routine operating procedures,” said Eric Donnenfield, MD, clinical professor of ophthalmology at New York University and president of the American Society of Cataract and Refractive Surgery. “Based on the results of the clinical trials, OMS302 has the potential to improve outcomes in all lens replacement surgeries.
“I look forward to being able to use the product in my practice-it provides benefits to both patients and their surgeons,” he said.
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.